Home  »  Business   »  Epizyme Inc. (NASDAQ: EPZM) Jumps 14.77%: What Cou...

Epizyme Inc. (NASDAQ: EPZM) Jumps 14.77%: What Could Be On The Way Going Forward?

Epizyme Inc. (NASDAQ:EPZM) shares, rose in value on Thursday, 05/12/22, with the stock price up by 14.77% to the previous day’s close as strong demand from buyers drove the stock to $0.54.

Actively observing the price movement in the last trading, the stock closed the session at $0.47, falling within a range of $0.4401 and $0.5936. The value of beta (5-year monthly) was 1.03. Referring to stock’s 52-week performance, its high was $9.86, and the low was $0.46. On the whole, EPZM has fluctuated by -32.90% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Epizyme Inc. currently standing at about $89.39 million, investors are eagerly awaiting this quarter’s results, scheduled for Aug 08, 2022 – Aug 12, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.29, which is expected to increase to -$0.25 for fiscal year -$1.39 and then to about -$1.06 by fiscal year 2023. Data indicates that the EPS growth is expected to be 43.30% in 2023, while the next year’s EPS growth is forecast to be 23.70%.

Analysts have estimated the company’s revenue for the quarter at $11.54 million, with a low estimate of $9.6 million and a high estimate of $13.98 million. According to the average forecast, sales growth in current quarter could jump down -11.30%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $46.87 million, representing an increase of 25.20% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that EPZM’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

5 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 3 recommend it as a Buy and 1 called the EPZM stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of EPZM currently trading nearly -22.03% and -47.40% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 33.06, while the 7-day volatility ratio is showing 22.51% which for the 30-day chart, stands at 14.08%. Furthermore, Epizyme Inc. (EPZM)’s beta value is 1.27, and its average true range (ATR) is 0.10. The company’s stock has been forecasted to trade at an average price of $5.92 over the course of the next 52 weeks, with a low of $0.60 and a high of $10.00. Based on these price targets, the low is -11.11% off current price, whereas the price has to move -1751.85% to reach the yearly target high. Additionally, analysts’ median price of $7.00 is likely to be welcomed by investors because it represents a decrease of -1196.3% from the current levels.

A comparison of Epizyme Inc. (EPZM) with its peers suggests the former has fared considerably weaker in the market. EPZM showed an intraday change of 14.77% in last session, and over the past year, it shrunk by -93.81%%. In comparison, Novartis AG (NVS) has moved higher at 1.59% on the day and was down -3.42% over the past 12 months. On the other hand, the price of Seagen Inc. (SGEN) has risen 6.40% on the day. The stock, however, is off -12.17% from where it was a year ago. Additionally, there is a gain of 9.56% for Dare Bioscience Inc. (DARE) in last trading while the stock has seen an overall depriciation of -16.94%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.33%.

Data on historical trading for Epizyme Inc. (NASDAQ:EPZM) indicates that the trading volumes over the past 3 months, they’ve averaged 2.27 million. According to company’s latest data on outstanding shares, there are 104.22 million shares outstanding.

Nearly 0.50% of Epizyme Inc.’s shares belong to company insiders and institutional investors own 72.20% of the company’s shares. The stock has fallen by -78.53% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the EPZM stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam